By Indication

C. difficile Infection (CDI) Market Analysis

Cross-industry research covering C. difficile Infection (CDI) across 1 market reportspanning Pharmaceuticals.

1 Reports

1 Industries

Reports Covering C. difficile Infection (CDI)

Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR

Pharmaceuticals·Market: USD 25.3 Billion (2025)·CAGR: 6.4%

CDI recurrence prevention is the fastest-growing indication sub-segment within bacterial HAI, driven by bezlotoxumab's biologic positioning and growing clinical acceptance of FMT (nct:NCT07348471). The FMT trial targeting ICU delirium via gut-brain axis modulation is an unconventional but scientifically credible pipeline signal for expanded microbiome-based HAI interventions.

11%

Market Share

7.1%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments